0000899243-20-024407.txt : 20200904 0000899243-20-024407.hdr.sgml : 20200904 20200904210136 ACCESSION NUMBER: 0000899243-20-024407 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200902 FILED AS OF DATE: 20200904 DATE AS OF CHANGE: 20200904 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brunecz Sharon CENTRAL INDEX KEY: 0001743787 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 201162796 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY, SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-02 0 0000896262 AMEDISYS INC AMED 0001743787 Brunecz Sharon 3854 AMERICAN WAY, SUITE A BATON ROUGE LA 70816 0 1 0 0 Chief Human Resources Officer Common Stock 2020-09-02 4 M 0 4367 93.76 A 22100 D Common Stock 2020-09-02 4 S 0 635 242.01 D 21465 D Common Stock 2020-09-02 4 S 0 1282 243.53 D 20183 D Common Stock 2020-09-02 4 S 0 103 244.88 D 20080 D Common Stock 2020-09-02 4 S 0 724 246.17 D 19356 D Common Stock 2020-09-02 4 S 0 1538 247.78 D 17818 D Common Stock 2020-09-02 4 S 0 85 248.37 D 17733 D Common Stock 117 I Through 401(k) Plan Stock Option (right to buy) 93.76 2020-09-02 4 M 0 4367 0.00 D 2028-07-27 Common Stock 4367 8734 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.65 to $242.45, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.04 to $244.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.88 to $245.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.05 to $246.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.34 to $248.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4. The information in this report is based on a plan statement dated as of June 30, 2020. On July 27, 2018, the reporting person was granted an option to purchase 17,468 shares of common stock, subject to time-based vesting. 4,367 of the options vested on each of July 27, 2019 and July 27, 2020, and the remaining 8,734 options vest ratably on each of July 27, 2021 and July 27, 2022, provided that the reporting person remains continuously employed by the Issuer on each such date, subject to pro-rated vesting provisions as provided in the award agreement for the stock options. /s/ Jennifer R. Guckert, pursuant to a power of attorney 2020-09-04